Neurocrine Biosciences Inc.

News & Events

Press Releases

In The Media

1. Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules

   PR Newswire NOV 20, 2025 8:30 AM EST
   Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 I...
   Read Article

2. Neurocrine Biosciences to Present at Upcoming Investor Conferences

   PR Newswire NOV 11, 2025 4:01 PM EST
   Neurocrine Biosciences to Present at Upcoming Investor Conferences PR Newswire SA...
   Read Article

3. Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder

   PR Newswire NOV 10, 2025 4:05 PM EST
   Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depre...
   Read Article

4. Neurocrine Biosciences Reports Third Quarter 2025 Financial Results

   PR Newswire OCT 28, 2025 4:01 PM EDT
   Neurocrine Biosciences Reports Third Quarter 2025 Financial Results PR Newswire Ac...
   Read Article

5. Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules

   PR Newswire OCT 17, 2025 8:30 AM EDT
   Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sust...
   Read Article

6. Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results

   PR Newswire OCT 7, 2025 4:01 PM EDT
   Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Resu...
   Read Article

7. Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise

   PR Newswire OCT 6, 2025 4:05 PM EDT
   Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsy...
   Read Article

8. Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea

   PR Newswire OCT 6, 2025 8:30 AM EDT
   Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and...
   Read Article

9. Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden

   PR Newswire SEP 23, 2025 8:30 AM EDT
   Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine...
   Read Article

10. Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder

    PR Newswire SEP 22, 2025 8:30 AM EDT
    Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults wit...
    Read Article